Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights:
Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy.
Concurrence with Alterity’s plan to target early stage MSA patients.
Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA.
Agreement that ATH434 has potential as a disease modifying treatment.
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2021 /PRNewswire/ — Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has received guidance from the European Medicines Agency
(EMA) regarding key aspects of the Company’s Phase 2 clinical trial for investigational drug ATH434 in the treatment of Multiple System Atrophy (MSA).

Related Keywords

Australia ,Melbourne ,Victoria ,David Stamler ,Company Phase ,Vanderbilt University Medical Center ,Drug Administration ,Nasdaq ,European Union ,European Medicines Agency ,Alterity Therapeutics Limited ,Alterity Therapeutics ,Medicinal Products ,Human Use ,Multiple System ,Multiple System Atrophy ,History Study ,Progressive Supranuclear Palsy ,ஆஸ்திரேலியா ,மெல்போர்ன் ,விக்டோரியா ,நிறுவனம் கட்டம் ,வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம் ,நாஸ்டாக் ,ஐரோப்பிய தொழிற்சங்கம் ,மருத்துவ ப்ராடக்ட்ஸ் ,மனிதன் பயன்பாடு ,பல அமைப்பு ,பல அமைப்பு அட்ரோஃபீ ,வரலாறு படிப்பு ,